{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:05:22Z","timestamp":1779433522374,"version":"3.53.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Effective cancer vaccines require delivery platforms that can simultaneously enhance immune responses, maintain safety, and simplify the formulation process. This study aimed to develop a novel vaccine delivery system based on the\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      -derived formyl peptide receptor-like 1 inhibitory protein (FLIPr), which naturally targets Fc\u03b3 receptors on antigen-presenting cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A recombinant variant, rF9R, was engineered by adding nine arginine residues to the C-terminus of FLIPr to facilitate electrostatic binding with anionic components. To optimize this interaction, epitopes were modified with five aspartic acid residues. The platform\u2019s ability to form stable complexes with peptides, CpG oligodeoxynucleotides, and protein antigens was evaluated. The efficacy of the rF9R\/rE7m complex was subsequently tested in tumor models to assess CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell activation and tumor regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The rF9R protein successfully bound peptides and antigens to form stable complexes, significantly enhancing antigen delivery and immune activation.\n                      <jats:italic>In vivo<\/jats:italic>\n                      results demonstrated that the rF9R\/rE7m complex\u2014both as a standalone treatment and when combined with CpG\u2014elicited robust CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell responses. This immune activation led to significant tumor regression in the studied models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The rF9R platform functions as both an efficient carrier and a potent immunostimulatory component. By providing a simple and versatile method for delivering peptide and subunit vaccines, rF9R represents a promising strategy for advancing cancer immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1831652","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:11:37Z","timestamp":1779430297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing cancer vaccine efficacy via electrostatic engineering of an Fc\u03b3R-targeted protein"],"prefix":"10.3389","volume":"17","author":[{"given":"Chiao-Chieh","family":"Wu","sequence":"first","affiliation":[{"name":"National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes","place":["Zhunan, Miaoli, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes","place":["Zhunan, Miaoli, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yi","family":"Chiang","sequence":"additional","affiliation":[{"name":"National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes","place":["Zhunan, Miaoli, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ling","family":"Tu","sequence":"additional","affiliation":[{"name":"National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes","place":["Zhunan, Miaoli, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jen","family":"Liu","sequence":"additional","affiliation":[{"name":"National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes","place":["Zhunan, Miaoli, Taiwan"]},{"name":"Graduate Institute of Biomedical Sciences, China Medical University","place":["Taichung, Taiwan"]},{"name":"Graduate Institute of Medicine, Kaohsiung Medical University","place":["Kaohsiung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsiang","family":"Leng","sequence":"additional","affiliation":[{"name":"National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes","place":["Zhunan, Miaoli, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisn-Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes","place":["Zhunan, Miaoli, Taiwan"]},{"name":"Graduate Institute of Biomedical Sciences, China Medical University","place":["Taichung, Taiwan"]},{"name":"Graduate Institute of Medicine, Kaohsiung Medical University","place":["Kaohsiung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","article-title":"Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (Concord-2)","volume":"385","author":"Allemani","year":"2015","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(01)00449-4","article-title":"Dendritic cells: Specialized and regulated antigen processing machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3390\/vaccines11111633","article-title":"Recent advances in cancer immunotherapy with a focus on Fda-approved vaccines and neoantigen-based vaccines","volume":"11","author":"Hargrave","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy Mrna-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (Keynote-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24404","article-title":"Current status and future of cancer vaccines: A bibliographic study","volume":"10","author":"Yu","year":"2024","journal-title":"Heliyon"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103905","article-title":"Nanomedicines as enhancers of tumor immunogenicity to augment cancer immunotherapy","volume":"29","author":"Dogheim","year":"2024","journal-title":"Drug Discov Today"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01839","article-title":"Delivery of antigen to Cd8(+) dendritic cells by fusing antigen with formyl peptide receptor-like 1 inhibitor protein induces antitumor immunity","volume":"10","author":"Chiang","year":"2019","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.751883","article-title":"Intranasal vaccination with recombinant antigen-Flipr fusion protein alone induces long-lasting systemic antibody responses and broad T cell responses","volume":"12","author":"Hsieh","year":"2021","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040970","article-title":"Recombinant lipidated Hpv E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model","volume":"7","author":"Huang","year":"2012","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2165\/11316930-000000000-00000","article-title":"Cpg oligodeoxynucleotides as Tlr9 agonists: Therapeutic applications in cancer","volume":"23","author":"Murad","year":"2009","journal-title":"BioDrugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41541-023-00680-4","article-title":"Recombinant lipidated Flipr effectively enhances mucosal and systemic immune responses for various vaccine types","volume":"8","author":"Hsieh","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.10.027","article-title":"A novel emulsion-type adjuvant containing Cpg oligodeoxynucleotides enhances Cd8+ T-cell-mediated anti-tumor immunity","volume":"173","author":"Song","year":"2014","journal-title":"J Control Release"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.3.1625","article-title":"Linear Padre T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer Igg antibody responses","volume":"164","author":"Alexander","year":"2000","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01876-6","article-title":"Toll-like receptor 9 agonists and combination therapies: Strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity","volume":"127","author":"Dongye","year":"2022","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/pharmaceutics18010011","article-title":"A systematic review of advanced drug delivery systems: Engineering strategies, barrier penetration, and clinical progress (2016-April 2025)","volume":"18","author":"Uzakova","year":"2025","journal-title":"Pharmaceutics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2012.10.003","article-title":"Advanced materials and processing for drug delivery: The past and the future","volume":"65","author":"Zhang","year":"2013","journal-title":"Adv Drug Delivery Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.3.1406","article-title":"Cutting edge: Cognate Cd4 help promotes recruitment of antigen-specific Cd8 T cells around dendritic cells","volume":"177","author":"Beuneu","year":"2006","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4110\/in.2023.23.e41","article-title":"The role of Cd4 T cell help in Cd8 T cell differentiation and function during chronic infection and cancer","volume":"23","author":"Topchyan","year":"2023","journal-title":"Immune Netw"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102345","article-title":"The multifaceted roles of Cd4(+) T cells and Mhc class Ii in cancer surveillance","volume":"83","author":"Bawden","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1322","article-title":"Cd4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of Cd8+ T lymphocytes","volume":"70","author":"Bos","year":"2010","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2025.107022","article-title":"Cd4(+) T-cell help delivery to monocyte-derived dendritic cells promotes effector differentiation of helper and cytotoxic T cells","volume":"275","author":"Bosma","year":"2025","journal-title":"Immunol Lett"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e014041","DOI":"10.1136\/jitc-2025-014041","article-title":"Stem-like Pd-1(+)Tcf-1(+) Cd8(+) T cells result from helpless priming and rely on Cd4(+) T-cell help to complete their cytotoxic effector differentiation","volume":"14","author":"Busselaar","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1808849116","article-title":"Cd4(+) T help promotes influenza virus-specific Cd8(+) T cell memory by limiting metabolic dysfunction","volume":"116","author":"Cullen","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e164258","DOI":"10.1172\/JCI164258","article-title":"Linked Cd4+\/Cd8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression","volume":"133","author":"Dolina","year":"2023","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00615-0","article-title":"Stem-like exhausted and memory Cd8(+) T cells in cancer","volume":"23","author":"Gebhardt","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.coi.2017.07.004","article-title":"Vaccines targeting helper T cells for cancer immunotherapy","volume":"47","author":"Melssen","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.12.8243","article-title":"Cd4 T cells are required for Cd8 T cell survival during both primary and memory recall responses","volume":"179","author":"Novy","year":"2007","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.05.025","article-title":"Prolonged but finite antigen presentation promotes reversible defects of \u201chelpless\u201d memory Cd8(+) T cells","volume":"58","author":"van der Heide","year":"2025","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.10.009","article-title":"Cd4(+) T cell help is required for the formation of a cytolytic Cd8(+) T cell subset that protects against chronic infection and cancer","volume":"51","author":"Zander","year":"2019","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1039\/d0na00716a","article-title":"Kinetics of nanoparticle uptake into and distribution in human cells","volume":"3","author":"Aberg","year":"2021","journal-title":"Nanoscale Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124799","article-title":"Effects of nanoparticle size, shape, and zeta potential on drug delivery","volume":"666","author":"Ozturk","year":"2024","journal-title":"Int J Pharm"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1113312","article-title":"The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s44313-025-00119-w","article-title":"Macrophage polarization in hematologic cancers: Mechanisms and therapeutic strategies","volume":"61","author":"Chen","year":"2026","journal-title":"Blood Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c17200","article-title":"An intracellular gelated macrophage-based vaccine for tumor immunotherapy","volume":"20","author":"An","year":"2026","journal-title":"ACS Nano"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-026-07840-4","article-title":"Adjuvant choice shapes macrophage activation and cytokine responses to freeze-thaw breast cancer antigens","author":"Ihlamur","year":"2026","journal-title":"BMC Res Notes"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1707183","article-title":"Advances in the application of tumor vaccines and combination strategies: New perspectives in lung cancer treatment","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831652\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:11:38Z","timestamp":1779430298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831652\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1831652"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1831652","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"1831652"}}